Bedford, MA, United States
Bedford, MA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | June 6, 2017
Site: www.businesswire.com

BOSTON--(BUSINESS WIRE)--Outcome Capital, an investment banking firm that serves middle market growth companies in the life science and technology segments, today announced that UCB Pharma, Ltd. has acquired privately held Beryllium Discovery, LLC. Beryllium, a specialized drug discovery contract research organization (CRO), provides research services and engages in collaborations with leading pharmaceutical, innovative biotechnology, and academic partners based on its innovative drug discovery platform. Outcome Capital served as the exclusive strategic and financial advisor to Beryllium for the transaction. Using a biology-first, target-centric approach, Beryllium has developed deep expertise in protein engineering, expression and purification, as well as functional biology and protein structure designed to find unique therapeutic drugs. The company has had a long and successful partnership with UCB, a developer of treatments for severe neurological and immunological diseases, which previously acquired a minority stake in Beryllium. Dr. Oded Ben-Joseph, Managing Director of Outcome Capital, commented: “Beryllium is a best-in-class and truly innovative CRO, and we congratulate them on this achievement. Through its expertise in drug discovery, the organization has been instrumental in bringing multiple paradigm-shifting drugs to market or to advanced clinical stages. With these two companies’ long history of successful collaboration, this transaction was an excellent match for our client. It is also a great strategic fit for UCB, and is expected to help grow their pipeline.” In addition to its drug discovery achievements, Beryllium’s scientific team has published more than 150 high-profile journal articles and contributed more than 1% of all structures deposited in the public protein data bank. Johan Pontin, CEO of Beryllium Discovery commented: “We are proud of our scientific achievements, and this deal is the ultimate recognition of our success. Our talented partners at UCB are in a great position to further build Beryllium’s platform and use it to bring more innovation to their high-value discovery program. This is also a great outcome for all Beryllium stakeholders, and I was very impressed with Outcome Capital’s ability to make it happen.” Beryllium’s mission is to provide best-in-class lead discovery solutions. The company’s proven teams of drug discovery professionals are passionate about unlocking the therapeutic potential of both genetically- and clinically-validated drug targets, and in developing new therapeutic modalities. Beryllium works in partnership with pharma and biotech clients to address the most difficult scientific and business challenges facing drug discovery, and to ultimately enable transformational health care outcomes. Outcome Capital is a unique investment banking firm that provides middle-market growth companies in the life sciences, healthcare services and technology markets with a value-added client-centric approach to merger, acquisition and corporate finance advisory services. The firm utilizes its proven approach to value enhancement by assisting boards and management teams in navigating both the financial and strategic markets and in implementing the best path for success. Outcome Capital’s strength stems from its unique ability to draw on its wide range of operational, strategic and transactional experience, its expertise across the value chain, and its broad industry relationships. The professionals at Outcome Capital take pride in their ability to help their clients to make well-informed strategic decisions and recognize the full value created by their vision. For more information, visit: www.outcomecapital.com.


Appleby T.C.,Gilead Sciences | Perry J.K.,Gilead Sciences | Murakami E.,Gilead Sciences | Barauskas O.,Gilead Sciences | And 9 more authors.
Science | Year: 2015

Nucleotide analog inhibitors have shown clinical success in the treatment of hepatitis C virus (HCV) infection, despite an incomplete mechanistic understanding of NS5B, the viral RNA-dependent RNA polymerase. Here we study the details of HCV RNA replication by determining crystal structures of stalled polymerase ternary complexes with enzymes, RNA templates, RNA primers, incoming nucleotides, and catalytic metal ions during both primed initiation and elongation of RNA synthesis. Our analysis revealed that highly conserved active-site residues in NS5B position the primer for in-line attack on the incoming nucleotide. A β loop and a C-terminal membrane-anchoring linker occlude the active-site cavity in the apo state, retract in the primed initiation assembly to enforce replication of the HCV genome from the 3′ terminus, and vacate the active-site cavity during elongation.We investigated the incorporation of nucleotide analog inhibitors, including the clinically active metabolite formed by sofosbuvir, to elucidate key molecular interactions in the active site. © 2015, American Association for the Advancement of Science. All rights reserved.


Gelinas A.D.,SomaLogic | Davies D.R.,Beryllium | Janjic N.,SomaLogic
Current Opinion in Structural Biology | Year: 2016

Understanding the structural rules that govern specific, high-affinity binding characteristic of aptamer-protein interactions is important in view of the increasing use of aptamers across many applications. From the modest number of 16 aptamer-protein structures currently available, trends are emerging. The flexible phosphodiester backbone allows folding into precise three-dimensional structures using known nucleic acid motifs as scaffolds that orient specific functional groups for target recognition. Still, completely novel motifs essential for structure and function are found in modified aptamers with diversity-enhancing side chains. Aptamers and antibodies, two classes of macromolecules used as affinity reagents with entirely different backbones and composition, recognize protein epitopes of similar size and with comparably high shape complementarity. © 2016.


Patent
Northern Illinois University and Beryllium | Date: 2016-03-09

Antibacterial and antimalarial IspF inhibitor compounds and compositions are described. Methods include administering described compounds and compositions to treat bacterial or parasitic infections and to inhibit parasite or bacterial growth.


Manufacturers add product variants in one product family to meet customers' different preferences. Components could be shared and reused to reduce costs. Demand and demand variance change with different sale prices under the stochastic and price-sensitive demand environment. Demand uncertainty has significant effects on costs and profits of the supply chain. With a numerical example involving a product family of cordless drills, a model is used to investigate the effect of supplier profit rate, cost reduction, and component commonality on the supply chain performance. Results show that saving in upstream suppliers due to component commonality could be passed to the manufacturer, retailer, and customers with appropriate coordination models such as quantity discount. With reduced procedure cost, a win-win pricing strategy for one supplier is to increase its profit at a rate while sell its products at a cheaper sale price based on the cost mark-up method considering the demand uncertainty from buyers or downstream suppliers in the supply chain. Copyright © 2011 Inderscience Enterprises Ltd.


Zhang T.,Beryllium
Yejin Fenxi/Metallurgical Analysis | Year: 2013

The beryllium copper intermediate alloy sample was dissolved by nitric acid to determine the content of aluminum. The pH of solution was adjusted to 6-7 using ammonia water. The iron and aluminum were precipitated in form of hydroxide. After filtration and washing, they were separated from matrix copper. The precipitation was dissolved with hydrochloric acid. In HAc-NaAc buffer solution at pH 5.0, aluminum reacted with 8-hydroxyquinoline to form complex, which was extracted with chloroform. The maximum absorption wavelength of complex was at 393 nm, and the apparent molar absorptivity was 6.45×103 L·mol-1·cm-1. In chloroform coloring solution, the Beer's law was obeyed for aluminum ion with mass concentration of 0-4000 μg/L. The interference ions such as iron and copper were removed by cupron-chloroform extraction before coloring. This method was applicable for the determination of 0.0002%-0.5% aluminum in beryllium copper intermediate alloy. The results were consistent with those obtained by ICP-AES. The recoveries of standard addition were 98%-102%.


Patent
Beryllium | Date: 2012-02-16

The beryllium content of beryllium aluminum alloys suitable for investment casting which contain a small but suitable amount of silver can be significantly reduced without adversely affecting their thermal or investment casting properties by including significantly more silicon in the alloy than done in the past.


Trademark
Beryllium | Date: 2014-01-23

Protein Reagents for Scientific or Research Use. Software Systems for Scientific or Research Use. Research, development, testing, management and consulting services in fields of drug discovery, health care and life sciences.


Trademark
Beryllium | Date: 2014-01-23

Protein Reagents for Scientific or Research Use. Software Systems for Scientific or Research Use. Research, development, testing, management and consulting services in fields of drug discovery, health care and life sciences.


Loading Beryllium collaborators
Loading Beryllium collaborators